BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9457403)

  • 1. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience.
    Huland E; Heinzer H; Mir TS; Huland H
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S98-105. PubMed ID: 9457403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).
    Huland E; Heinzer H; Huland H
    Anticancer Res; 1999; 19(4A):2679-83. PubMed ID: 10470219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of interleukin-2 inhalation therapy.
    Huland E; Heinzer H; Huland H; Yung R
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
    Huland E; Heinzer H; Huland H
    Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
    Huland E; Heinzer H; Huland H
    Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
    Huland E; Heinzer H; Huland H
    J Cancer Res Clin Oncol; 1994; 120(4):221-8. PubMed ID: 8288676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter].
    Heinzer H; Huland E; Aalamian M; Huland H
    Urologe A; 1999 Sep; 38(5):466-73. PubMed ID: 10501705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhaled immunotherapy for pulmonary metastases of renal cell cancer].
    Lümmen G; Schenck M; Börgermann C; Eisenhardt A; Vom Dorp F; Sperling H; Rübben H
    Urologe A; 2004 Apr; 43(4):457-61. PubMed ID: 15085267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2.
    Esteban-González E; Carballido J; Navas V; Torregrosa Z; Muñoz A; de Mon MA;
    Anticancer Drugs; 2007 Mar; 18(3):291-6. PubMed ID: 17264761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy.
    Huland E; Heinzer H; Jörres RA; Loppow D; Huland H
    Urologe A; 2004 Sep; 43 Suppl 3():S140-4. PubMed ID: 15179553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma.
    Huland E; Huland H; Heinzer H
    J Urol; 1992 Feb; 147(2):344-8. PubMed ID: 1732590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2.
    Merimsky O; Gez E; Weitzen R; Nehushtan H; Rubinov R; Hayat H; Peretz T; Ben-Shahar M; Biran H; Katsenelson R; Mermershtein V; Loven D; Karminsky N; Neumann A; Matcejevsky D; Inbar M
    Ann Oncol; 2004 Apr; 15(4):610-2. PubMed ID: 15033668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regional immunotherapy of metastatic renal cell carcinoma].
    Heinzer H; Huland E; Huland H
    Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC; Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients.
    Gitlitz BJ; Hoffman DM; Moldawer N; Belldegrun A; Figlin RA
    Cancer J; 2001; 7(2):112-20. PubMed ID: 11324764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma.
    Nakamoto T; Kasaoka Y; Mitani S; Usui T
    Int J Urol; 1997 Jul; 4(4):343-8. PubMed ID: 9256321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.